Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins.

AIM OF THE STUDY Health-related networks like patient health forums may be considered as potential sources of information to early detect pharmacovigilance issues or complete data on drug safety. However, the clinical and pharmacological relevancy of such a source has not been clearly explored. We aimed to describe the characteristics and the informativeness level of Internet narratives posted by patients and mentioning adverse drug reactions (ADRs) related to statins. METHODS A retrospective cross-sectional study was conducted on an Internet website dedicated to share experience on medicines. One day of December 2012, postings about simvastatin, rosuvastatin and atorvastatin publicly available on the website were collected. Their informativeness according to 16 key elements of information (including drug start and stop date, duration of treatment, time to onset and duration of the ADR, outcome, medical history, concomitant medication) was assessed. General information about reported ADRs was also investigated. RESULTS Among the 96 postings related to statins, 72 (40 women, 32 men; mean age: 59 [40-78]) mentioned at least one ADR accounting for a total of 176 ADRs. Musculoskeletal and connective tissue disorders (42.6%) and nervous system disorders (15.3%) were the main represented ADRs. Only 2 patients mentioned ADRs that could be considered as serious but 24 patients mentioned they stopped or switched their treatment toward another lipid modifying agent because of the ADR. Mean number of available key elements of information per narrative was 6/16. Time to onset and duration of the ADR were respectively available in only 31% and 3% of the narratives. Medical history and concomitant medication were respectively lacking in 87% and 86% of the narratives. Outcome was found only in 39% of the narratives. CONCLUSION Patient narratives posted on Internet include mainly non-serious expected ADR. However, their informativeness level is very incomplete and makes difficult their assessment and use for pharmacovigilance purpose.

[1]  J. Hewitt,et al.  Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. , 2015, British journal of clinical pharmacology.

[2]  Afonso Cavaco,et al.  The value of patient reporting to the pharmacovigilance system: a systematic review , 2017, British journal of clinical pharmacology.

[3]  Taha A. Kass-Hout,et al.  Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter , 2014, Drug Safety.

[4]  S. Golder,et al.  Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. , 2015, British journal of clinical pharmacology.

[5]  Pushpraj Shukla,et al.  Early identification of adverse drug reactions from search log data , 2016, J. Biomed. Informatics.

[6]  L Pochard,et al.  Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator®) withdrawal in France , 2014, Journal of clinical pharmacy and therapeutics.

[7]  Ryen W. White,et al.  Toward Enhanced Pharmacovigilance Using Patient-Generated Data on the Internet , 2014, Clinical pharmacology and therapeutics.

[8]  Jan A. Kors,et al.  Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies , 2015, Drug Safety.

[9]  C M Bond,et al.  Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. , 2011, Health technology assessment.

[10]  Jean-Baptiste Richard,et al.  Use of the Internet as a Health Information Resource Among French Young Adults: Results From a Nationally Representative Survey , 2014, Journal of medical Internet research.

[11]  A. Pariente,et al.  Impact of a public media event on the use of statins in the French population. , 2017, Archives of cardiovascular diseases.

[12]  Graciela Gonzalez-Hernandez,et al.  Utilizing social media data for pharmacovigilance: A review , 2015, J. Biomed. Informatics.

[13]  S. Wilkes,et al.  Important information regarding reporting of adverse drug reactions: a qualitative study , 2014, The International journal of pharmacy practice.

[14]  Abeed Sarker,et al.  Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features , 2015, J. Am. Medical Informatics Assoc..

[15]  Marc Van Audenrode,et al.  Can social media data lead to earlier detection of drug‐related adverse events? , 2016, Pharmacoepidemiology and drug safety.

[16]  Rajesh Ghosh,et al.  Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media , 2015, Expert opinion on drug safety.

[17]  J. Montastruc,et al.  Analysis of chats on French internet forums about drugs and pregnancy , 2014, Pharmacoepidemiology and drug safety.

[18]  F. van Hunsel,et al.  Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. , 2009, British journal of clinical pharmacology.

[19]  F. Haramburu,et al.  Causality assessment in pharmacovigilance: The French method and its successive updates. , 2016, Therapie.

[20]  D. Bertram,et al.  Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries , 2014, Drug Safety.

[21]  W. Chou,et al.  Social Media Use in the United States: Implications for Health Communication , 2009, Journal of medical Internet research.

[22]  A. Burgun,et al.  Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review , 2015, Journal of medical Internet research.

[23]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[24]  M. Laroche,et al.  Statines et troubles musculaires : comparaison des notifications par les patients et les professionnels de santé , 2005 .

[25]  Joel E Dimsdale,et al.  Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. , 2012, Archives of internal medicine.

[26]  J. Montastruc,et al.  Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance? , 2016, Therapie.

[27]  A. Blenkinsopp,et al.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. , 2007, British journal of clinical pharmacology.

[28]  S. Wilkes,et al.  Adverse drug reaction reports of patients and healthcare professionals—differences in reported information , 2015, Pharmacoepidemiology and drug safety.

[29]  J. Montastruc,et al.  Undesirable Effects Related to Oral Antineoplastic Drugs: Comparison Between Patients’ Internet Narratives and a National Pharmacovigilance Database , 2014, Drug Safety.

[30]  John D Seeger,et al.  Drug safety in the digital age. , 2014, The New England journal of medicine.